Pharmaceuticals in Germany
Pharmaceuticals in Germany
SUMMARY
Pharmaceuticals in Germany industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Pharmaceuticals in Germany industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The German pharmaceuticals market had total revenues of $40,200.0m in 2019, representing a compound annual growth rate (CAGR) of 0.6% between 2015 and 2019.
- The German government’s decision to increase its focus on the use of generic medicines to reduce healthcare spending and maintain economic stability has resulted in decreasing volumes and a downward pricing pressure on existing drugs.
- The market has been supported to some degree by Germany’s aging population and an increase in age-associated disease, such as diabetes and cardiovascular diseases.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Germany
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Germany
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Germany pharmaceuticals market with five year forecasts
- What was the size of the Germany pharmaceuticals market by value in 2019?
- What will be the size of the Germany pharmaceuticals market in 2024?
- What factors are affecting the strength of competition in the Germany pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Germany's pharmaceuticals market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. What has been the rationale behind recent strategic partnerships?
7.6. What threats do leading players face?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. F. Hoffmann-La Roche Ltd
8.3. Bayer AG
8.4. Boehringer Ingelheim GmbH
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Market share
7.2. Who are the leading players?
7.3. What are the strengths/weaknesses of leading players?
7.4. What strategies do leading players follow?
7.5. What has been the rationale behind recent strategic partnerships?
7.6. What threats do leading players face?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. F. Hoffmann-La Roche Ltd
8.3. Bayer AG
8.4. Boehringer Ingelheim GmbH
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Germany pharmaceuticals market value: $ billion, 2015-19
Table 2: Germany pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Germany pharmaceuticals market share: % share, by value, 2019
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Annual Financial Ratios (Continued)
Table 8: Novartis AG: Key Employees
Table 9: Novartis AG: Key Employees Continued
Table 10: F. Hoffmann-La Roche Ltd: key facts
Table 11: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 12: F. Hoffmann-La Roche Ltd: Key Employees
Table 13: Bayer AG: key facts
Table 14: Bayer AG: Annual Financial Ratios
Table 15: Bayer AG: Key Employees
Table 16: Boehringer Ingelheim GmbH: key facts
Table 17: Boehringer Ingelheim GmbH: Key Employees
Table 18: Germany size of population (million), 2015-19
Table 19: Germany gdp (constant 2005 prices, $ billion), 2015-19
Table 20: Germany gdp (current prices, $ billion), 2015-19
Table 21: Germany inflation, 2015-19
Table 22: Germany consumer price index (absolute), 2015-19
Table 23: Germany exchange rate, 2015-19
Table 1: Germany pharmaceuticals market value: $ billion, 2015-19
Table 2: Germany pharmaceuticals market geography segmentation: $ billion, 2019
Table 3: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Table 4: Germany pharmaceuticals market share: % share, by value, 2019
Table 5: Novartis AG: key facts
Table 6: Novartis AG: Annual Financial Ratios
Table 7: Novartis AG: Annual Financial Ratios (Continued)
Table 8: Novartis AG: Key Employees
Table 9: Novartis AG: Key Employees Continued
Table 10: F. Hoffmann-La Roche Ltd: key facts
Table 11: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 12: F. Hoffmann-La Roche Ltd: Key Employees
Table 13: Bayer AG: key facts
Table 14: Bayer AG: Annual Financial Ratios
Table 15: Bayer AG: Key Employees
Table 16: Boehringer Ingelheim GmbH: key facts
Table 17: Boehringer Ingelheim GmbH: Key Employees
Table 18: Germany size of population (million), 2015-19
Table 19: Germany gdp (constant 2005 prices, $ billion), 2015-19
Table 20: Germany gdp (current prices, $ billion), 2015-19
Table 21: Germany inflation, 2015-19
Table 22: Germany consumer price index (absolute), 2015-19
Table 23: Germany exchange rate, 2015-19
LIST OF FIGURES
Figure 1: Germany pharmaceuticals market value: $ billion, 2015-19
Figure 2: Germany pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Germany, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Germany, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Germany, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2019
Figure 10: Germany pharmaceuticals market share: % share, by value, 2019
Figure 1: Germany pharmaceuticals market value: $ billion, 2015-19
Figure 2: Germany pharmaceuticals market geography segmentation: % share, by value, 2019
Figure 3: Germany pharmaceuticals market value forecast: $ billion, 2019-24
Figure 4: Forces driving competition in the pharmaceuticals market in Germany, 2019
Figure 5: Drivers of buyer power in the pharmaceuticals market in Germany, 2019
Figure 6: Drivers of supplier power in the pharmaceuticals market in Germany, 2019
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2019
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2019
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2019
Figure 10: Germany pharmaceuticals market share: % share, by value, 2019
